Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Just the word "cancer" is enough to fill many people with fright, but one 25-year-old has told Newsweek she is determined to show that a diagnosis—while incredibly challenging—need not mean death ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ward at Nottingham City Hospital. Mr Evans underwent a successful stem ...

An emotional two-year journey reached a heart-warming milestone as Newark’s miracle boy, who defied all the odds to ring his ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

China We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype ...

The proteins that make cell-to-cell cargo transport possible. ScienceDaily . Retrieved February 12, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250115165210.htm ...

Kinase Inhibitors These drugs block certain enzymes that control cell growth, helping to keep lymphoma cells from growing. Targeted therapy drugs may have side effects. The types of side effects ...